Literature DB >> 6601512

Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.

J Bubeník, P Perlmann, M Indrová, J Símová, T Jandlová, J Neuwirt.   

Abstract

Supernatants from Con A-stimulated rat spleen cell cultures containing T cell growth factor inhibited growth of a transplantable 3-methylcholanthrene-induced sarcoma in syngeneic mice. The tumour-inhibitory effects were dependent on the concentration of T cell growth factor and repeated injections of the supernatants.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6601512     DOI： 10.1007/bf00205362

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  14 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  Killer T cells in a Burkitt's lymphoma biopsy.

Authors:  M Jondal; E Svedmyr; E Klein; S Singh
Journal:  Nature       Date:  1975-05-29       Impact factor: 49.962

3.  Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors.

Authors: 
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

4.  T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice.

Authors:  H Wagner; C Hardt; K Heeg; M Röllinghoff; K Pfizenmaier
Journal:  Nature       Date:  1980-03-20       Impact factor: 49.962

Review 5.  Continuous cytotoxic T-cell lines.

Authors:  K A Smith
Journal:  Contemp Top Immunobiol       Date:  1980

6.  Solubilized tumour-associated antigens of methyl-cholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests.

Authors:  J Bubeník; M Indrová; S Nemecková; M Malkovský; B Von Broen; V Pálek; J Anderlíková
Journal:  Int J Cancer       Date:  1978-03-15       Impact factor: 7.396

7.  Biochemical characterization of lymphocyte regulatory molecules. II. Purification of a class of rat and human lymphokines.

Authors:  S Gillis; K A Smith; J Watson
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

8.  Purification of murine T cell growth factor. A lymphocyte mitogen with helper activity.

Authors:  A Granelli-Piperno; J D Vassalli; E Reich
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

9.  Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors.

Authors:  K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

10.  Immune response to chemically induced tumours: correlation of responding cell class with in vivo inhibition of tumour growth.

Authors:  M B Calderwood; J T Forbes; R T Smith
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640
View more
  17 in total

Review 1.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 2.  Local and regional immunotherapy of cancer with interleukin 2.

Authors:  J Bubeník
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.

Authors:  K I Naruo; S Hinuma; O Shiho; T Houkan; K Ootsu; K Tsukamoto
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

Review 4.  Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions.

Authors:  A L de Weck; F Kristensen; F Joncourt; F Bettens; C Walker; Y Wang
Journal:  Springer Semin Immunopathol       Date:  1984

5.  Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Authors:  Jennifer A A Gubbels; Brian Gadbaw; Ilia N Buhtoiarov; Sachi Horibata; Arvinder K Kapur; Dhara Patel; Jacquelyn A Hank; Stephen D Gillies; Paul M Sondel; Manish S Patankar; Joseph Connor
Journal:  Cancer Immunol Immunother       Date:  2011-07-27       Impact factor: 6.968

6.  Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study.

Authors:  Sonata Jarmalaite; Rasa Andrekute; Asta Scesnaite; Kestutis Suziedelis; Kirsti Husgafvel-Pursiainen; Feliksas Jankevicius
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-19       Impact factor: 4.553

Review 7.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 8.  Strategies for cytokine utilisation in tumor therapy.

Authors:  F Di Pierro; F Cavallo; F Pericle; S Bertini; M Giovarelli; G Forni
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

9.  Tumour inhibitory effects of TCGF/IL-2/-containing preparations.

Authors:  J Bubeník; M Indrová; P Perlmann; K Berzins; O Mach; J Kraml; A Toulcová
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.

Authors:  E Huland; H Heinzer; H Huland
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.